Cargando…

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Detalles Bibliográficos
Autores principales:	Ganan-Gomez, Irene, Yang, Hui, Ma, Feiyang, Montalban-Bravo, Guillermo, Thongon, Natthakan, Marchica, Valentina, Richard-Carpentier, Guillaume, Chien, Kelly, Manyam, Ganiraju, Wang, Feng, Alfonso, Ana, Chen, Shuaitong, Class, Caleb, Kanagal-Shamanna, Rashmi, Ingram, Justin P., Ogoti, Yamini, Rose, Ashley, Loghavi, Sanam, Lockyer, Pamela, Cambo, Benedetta, Muftuoglu, Muharrem, Schneider, Sarah, Adema, Vera, McLellan, Michael, Garza, John, Marchesini, Matteo, Giuliani, Nicola, Pellegrini, Matteo, Wang, Jing, Walker, Jason, Li, Ziyi, Takahashi, Koichi, Leverson, Joel D., Bueso-Ramos, Carlos, Andreeff, Michael, Clise-Dwyer, Karen, Garcia-Manero, Guillermo, Colla, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117132/ https://www.ncbi.nlm.nih.gov/pubmed/35484266 http://dx.doi.org/10.1038/s41591-022-01827-x

Ejemplares similares

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

S185: TARGETING DNA2 OVERCOMES METABOLIC REPROGRAMMING IN 1Q21 MULTIPLE MYELOMA
por: Thongon, Natthakan, et al.
Publicado: (2023)

Hematopoiesis under telomere attrition at the single-cell resolution
por: Thongon, Natthakan, et al.
Publicado: (2021)

Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
por: Adema, Vera, et al.
Publicado: (2022)

Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2019)

Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
por: Rodriguez-Sevilla, Juan Jose, et al.
Publicado: (2023)

P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS
por: Hein, Kimberly, et al.
Publicado: (2023)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report
por: Burgos, Sebastian, et al.
Publicado: (2019)

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
por: Zuo, Zhuang, et al.
Publicado: (2022)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
por: Shah, Shilpan, et al.
Publicado: (2014)

PB2481: OUTCOMES OF INDIVIDUALS WITH CLONAL HEMATOPOIESIS EVALUATED AT A CANCER CENTER
por: Chien, Kelly, et al.
Publicado: (2023)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

KPP: KEGG Pathway Painter
por: Manyam, Ganiraju, et al.
Publicado: (2015)

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
por: Quesada, Andrés E., et al.
Publicado: (2021)

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2023)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
por: Senapati, Jayastu, et al.
Publicado: (2023)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
por: Kantarjian, Hagop, et al.
Publicado: (2023)

An efficient algorithm for systematic analysis of nucleotide strings suitable for siRNA design
por: Baranova, Ancha, et al.
Publicado: (2011)

Integrative Analysis of mRNA, microRNA, and Protein Correlates of Relative Cerebral Blood Volume Values in GBM Reveals the Role for Modulators of Angiogenesis and Tumor Proliferation
por: Rao, Arvind, et al.
Publicado: (2016)

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
por: Mu-Mosley, Hong, et al.
Publicado: (2022)

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Extended live-cell barcoding approach for multiplexed mass cytometry
por: Muftuoglu, Muharrem, et al.
Publicado: (2021)

Gambogic Acid Inhibits Wnt/β-catenin Signaling and Induces ER Stress-Mediated Apoptosis in Human Cholangiocarcinoma
por: Suksen, Kanoknetr, et al.
Publicado: (2021)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Integrating multi-platform genomic data using hierarchical Bayesian relevance vector machines
por: Srivastava, Sanvesh, et al.
Publicado: (2013)

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
por: Yang, Hui, et al.
Publicado: (2022)

In-depth analysis of SARS-CoV-2–specific T cells reveals diverse differentiation hierarchies in vaccinated individuals
por: Li, Li, et al.
Publicado: (2022)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
por: Chien, Kelly, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aekeevn5h8clpo8vc31ovfnb14